News
Effective strategies to ensure the longevity and efficacy of pharmaceutical products
Pharmaceutical products stand as the pillars of patient treatment and wellbeing. Ensuring their longevity and efficacy is not just about the ingredients inside.
It also encompasses a broader spectrum of considerations from storage and stability to patient education. With evolving regulatory landscapes, advancing technology, and an ever-increasing focus on patient-centric care, the pharmaceutical industry faces both challenges and opportunities in guaranteeing the robustness of their products over time.
Achieving this balance requires a ton of meticulous research, cutting-edge technology, and patient collaboration. Today we’ll delve into the core strategies employed by industry leaders to ensure that the medicines we rely on retain their integrity and therapeutic promise throughout their shelf life.
Implement robust quality control and quality assurance systems
Beyond formulation, the longevity and efficacy of pharmaceuticals heavily rely on robust quality control and quality assurance systems.
The journey from raw materials to the final product is intricate, and without meticulous oversight, the risk of contamination or deviation from the set standards rises.
Implementing rigorous testing methods at each stage can help identify potential issues before they escalate. Moreover, Quality Assurance (QA) practices ensure that there’s consistency in product batches, maintaining their effectiveness over extended periods of time.
By adopting a culture of continuous improvement, pharmaceutical companies can adapt and evolve their quality systems in response to new scientific findings, regulatory changes, and real-world product performance.
Prioritise product stability from the outset
If a product can’t maintain its desired properties under varied environmental conditions, its therapeutic efficacy can diminish. It’s why companies invest significantly in stability storage and testing. Services like those provided by Broughton Group provide stability testing services.
They offer controlled environments to evaluate how a drug product reacts to factors such as temperature, humidity, and light. Such insights help in predicting the shelf life of the product, designing appropriate packaging, and providing storage instructions to ensure maximum efficacy.
Whatever stage your product is at, stability studies are a key component of determining shelf-life.
Understand and minimise degradation pathways
Every pharmaceutical product has inherent chemical properties that make it susceptible to specific degradation pathways. Therefore, recognising these pathways is crucial.
Degradation can occur due to various factors, such as light exposure, temperature variations, and reactions with other compounds.
Whether it’s hydrolysis, oxidation, or photolysis, understanding the triggers can help in formulating the product in a way that minimises degradation. Such proactive measures ensure that the product retains its efficacy and therapeutic properties for longer durations.
Provide patient education and proper dispensing
Even with the best stability protocols and QA systems, the responsibility falls on the patient to ensure a product’s longevity. Proper storage conditions, adhering to dosage recommendations, and understanding the product’s expiry can significantly influence its therapeutic efficiency.
Pharmacists and healthcare professionals play a pivotal role in this, providing guidelines on storage and educating patients about potential signs of product degradation.
Therefore, it’s important to provide patients with the information they need about your product.
Once these strategies are well in place, pharmaceutical products not only uphold their integrity but also instil a sense of trust and confidence among consumers.
The Femtech World Awards is proud to reveal the shortlist for Research Project of the Year as part of the third annual global celebration of innovation, impact and leadership across women’s health.
From fertility science and perimenopause research to regional ecosystem analysis, the shortlisted projects reflect the breadth and growing influence of femtech research worldwide.
The category is sponsored by OncoGenomX, with the winner to be selected by a representative from the organisation.
OncoGenomX is dedicated to offering solutions and providing comprehensive support services that empower Drug Developers, Clinical Researchers, Oncologists,NextGenSeq Diagnostics Laboratories, NextGenSeq Service Organisations, Cancer Diagnostics and Therapeutics Companies to achieve their ambitious goals
The shortlisted entries for Research Project of the Year are:
Women’s health remains significantly underserved in South-East Asia, with persistent gaps in access, awareness, and quality of care carrying substantial social and economic costs.
This report examines the femtech landscape in Indonesia, the Philippines, Singapore, Thailand, and Vietnam, highlighting market trends, emerging technologies including artificial intelligence, and the evolving support ecosystem.
It identifies key challenges facing femtech founders, including limited access to finance, low awareness and persistent stigma, marketing constraints linked to content moderation, and gaps in tailored ecosystem support.
Led by Stephanie Willson, MD, of the IVI RMA Global Research Alliance, the study explored whether embryos that show certain chromosome abnormalities during genetic testing may still have the potential to result in a healthy pregnancy and live birth.
The research analysed more than 7,600 frozen embryo transfers and found that some embryos previously considered unlikely to succeed were still capable of leading to successful pregnancies, although at lower rates than embryos without abnormalities.
The findings could help fertility clinics and patients make more informed decisions during IVF treatment, particularly in cases where there are limited embryos available.
Rather than automatically discarding these embryos, the research supports a more evidence-based and personalised approach to fertility care.
For many women, perimenopause can feel confusing and unpredictable, with limited research explaining what is happening in their bodies.
Natural Cycles set out to change that by leading one of the largest studies ever conducted on menstrual and ovulatory patterns, uncovering new insights into how ovulation behaves as women approach menopause.
Conducted in collaboration with researchers from George Washington University, Seattle Clinical Research Center, Gennev and the University of California San Diego, the study analysed nearly one million menstrual cycles from more than 197,000 women aged 18–52 across more than 140 countries.
The scale of this dataset made it possible to explore menstrual patterns and ovulation in far greater detail than has traditionally been possible in women’s health research.
The Femtech World Awards celebrates the innovators, researchers and organisations driving meaningful progress in women’s health.
What happens next
Winners across all categories will be revealed during the virtual ceremony on June 19, with winners receiving a trophy and an interview with a Femtech World journalist.
Women over 40 are seeking raves for mental and physical wellbeing, with a study suggesting the benefits go beyond nightlife.
The findings challenge the idea that nightlife and electronic dance music events are mainly for younger people.
Published in Psychology of Music, the study focused on the common misconception that nightlife is only for younger audiences.
Researchers surveyed 136 female clubbers aged 40 to 65 about their experiences at electronic dance music events.
The study, carried out at the University of Leeds in England, found women reported mental and physical wellbeing benefits from attending these events.
Seeing favourite DJs was the most common motivation, but many women also described dancing as a way to relieve stress and find emotional support.
The research found that 65.9 per cent of participants described attending a rave as “spiritual”, while 62.9 per cent said it offered an escape from everyday life.
A further 58.3 per cent said they felt like a different version of themselves in a club environment.
Nine in ten participants said they felt at home at electronic dance music events, with many pointing to a shared passion for music and the sense of community around it.
The study also suggested physical fitness played a role, with some women saying they had made clubbing part of their regular exercise routine.
However, the findings also highlighted challenges for older women in nightlife spaces.
One fifth of participants said they felt visibly out of place because of their age.
Nearly half reported unwanted physical contact, leading some to seek out different venues or attend only with friends.
Osteoporosis may raise the risk of death in postmenopausal women by up to 47 per cent, a new study suggests.
The findings point to an inverse relationship between femoral bone mineral density and mortality risk, especially within certain ranges.
Femoral bone mineral density is the amount of mineral in the thigh bone, which is often measured to assess bone strength and osteoporosis risk.
Dr Monica Christmas is associate medical director for The Menopause Society.
She said: “Osteoporosis often remains a silent threat after menopause, despite its profound effect on women’s lives—from loss of height, poor balance, and reduced mobility to disfigurement, pain, and even premature death.
“Early screening and preventive measures, including a calcium-rich diet (preferably from food sources), regular weight-bearing exercise, and hormone therapy when appropriate, can significantly improve bone health and reduce risks not only of fractures but also cardiovascular disease, certain cancers, and dementia.
“It’s time we bring this conversation to the forefront.”
In the study involving nearly 3,000 postmenopausal women, bone mineral density at four femoral sites was assessed using dual-energy x-ray absorptiometry, a scan commonly used to measure bone strength and fracture risk.
The analysis found that mortality risk was significantly higher when femoral bone mineral density reached the osteoporotic threshold or when osteoporotic fractures were present.
After full adjustment, osteoporosis was associated with a 47 per cent increased risk of mortality.
A stronger inverse association between increased bone mineral density and mortality risk was seen within specific ranges, suggesting bone mineral density could serve as a prognostic marker of wider health.
The relationship appeared especially notable within the range of 0.46 to 0.71 g/cm² for total femur bone mineral density.
Previous research has shown that postmenopausal women face a significantly higher risk of death within one year of hip or vertebral fractures.
Fertility3 weeks agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
News2 weeks agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
Fertility4 weeks agoFuture Fertility partners with Japan’s leading IVF provider, Kato Ladies Clinic
Diagnosis3 weeks agoNew meta-analysis further supports low re-excisions and high placement accuracy with the Magseed marker
Menopause4 weeks agoMore research needed to understand link between brain fog and menopause, expert says
Mental health3 weeks agoLifting weights shows mental health and cognitive benefits in older women, study finds
News3 weeks agoResistance training has preventative effects in menopause, study finds
Pregnancy3 weeks agoNIPT or NT scan? Why the 2026 evidence supports doing Both